KDx Diagnostics, Inc., announced today that it has received Conformité Européene (CE) Marking for its innovative and proprietary urine-based test (the URO17™ test) for bladder cancer … Read More
Uncategorized07/03/20 KDx Diagnostics Announces CE Marking for Innovative Non-invasive URO17™ Bladder Cancer Test
July 26, 20200
